136 related articles for article (PubMed ID: 8419351)
41. Inhibition of prothrombinase by antithrombin-heparin at a macroscopic surface.
Speijer H; Billy D; Willems G; Hemker HC; Lindhout T
Thromb Haemost; 1995 Apr; 73(4):648-53. PubMed ID: 7495073
[TBL] [Abstract][Full Text] [Related]
42. Engineered recombinant factor VII Q217 variants with altered inhibitor specificities.
Chang YJ; Hamaguchi N; Chang SC; Ruf W; Shen MC; Lin SW
Biochemistry; 1999 Aug; 38(34):10940-8. PubMed ID: 10460149
[TBL] [Abstract][Full Text] [Related]
43. Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin-proteinase reactions. Resolution of the antithrombin conformational change contribution to heparin rate enhancement.
Olson ST; Björk I; Sheffer R; Craig PA; Shore JD; Choay J
J Biol Chem; 1992 Jun; 267(18):12528-38. PubMed ID: 1618758
[TBL] [Abstract][Full Text] [Related]
44. Cooperative activation of human factor IX by the human extrinsic pathway of blood coagulation.
Lawson JH; Mann KG
J Biol Chem; 1991 Jun; 266(17):11317-27. PubMed ID: 2040636
[TBL] [Abstract][Full Text] [Related]
45. Mechanisms of binding of recombinant extrinsic pathway inhibitor (rEPI) to cultured cell surfaces. Evidence that rEPI can bind to and inhibit factor VIIa-tissue factor complexes in the absence of factor Xa.
Callander NS; Rao LV; Nordfang O; Sandset PM; Warn-Cramer B; Rapaport SI
J Biol Chem; 1992 Jan; 267(2):876-82. PubMed ID: 1730676
[TBL] [Abstract][Full Text] [Related]
46. Neutralization and binding of heparin by S protein/vitronectin in the inhibition of factor Xa by antithrombin III. Involvement of an inducible heparin-binding domain of S protein/vitronectin.
Preissner KT; Müller-Berghaus G
J Biol Chem; 1987 Sep; 262(25):12247-53. PubMed ID: 2442161
[TBL] [Abstract][Full Text] [Related]
47. The M358R variant of α(1)-proteinase inhibitor inhibits coagulation factor VIIa.
Sheffield WP; Bhakta V
Biochem Biophys Res Commun; 2016 Feb; 470(3):710-713. PubMed ID: 26797521
[TBL] [Abstract][Full Text] [Related]
48. High molecular weight kininogen potentiates the heparin-accelerated inhibition of plasma kallikrein by antithrombin: role for antithrombin in the regulation of kallikrein.
Olson ST; Sheffer R; Francis AM
Biochemistry; 1993 Nov; 32(45):12136-47. PubMed ID: 7692967
[TBL] [Abstract][Full Text] [Related]
49. The heparin-enhanced antithrombin III/thrombin reaction is saturable with respect to both thrombin and antithrombin III.
Griffith MJ
J Biol Chem; 1982 Dec; 257(23):13899-302. PubMed ID: 7142182
[TBL] [Abstract][Full Text] [Related]
50. Expression of human soluble tissue factor in yeast and enzymatic properties of its complex with factor VIIa.
Shigematsu Y; Miyata T; Higashi S; Miki T; Sadler JE; Iwanaga S
J Biol Chem; 1992 Oct; 267(30):21329-37. PubMed ID: 1400445
[TBL] [Abstract][Full Text] [Related]
51. Effect of a pentosan polysulphate upon thrombin and factor Xa inactivation by antithrombin III.
Scully MF; Kakkar VV
Biochem J; 1984 Sep; 222(3):571-8. PubMed ID: 6207810
[TBL] [Abstract][Full Text] [Related]
52. Inhibition of urokinase by complex formation with human antithrombin III in absence and presence of heparin.
Clemmensen I
Thromb Haemost; 1978 Jun; 39(3):616-23. PubMed ID: 705690
[TBL] [Abstract][Full Text] [Related]
53. Tissue factor-dependent autoactivation of human blood coagulation factor VII.
Yamamoto M; Nakagaki T; Kisiel W
J Biol Chem; 1992 Sep; 267(27):19089-94. PubMed ID: 1527033
[TBL] [Abstract][Full Text] [Related]
54. The inhibition of the anticoagulant activity of heparin by platelets, brain phospholipids, and tissue factor.
Ofosu FA; Cerskus AL; Hirsh J; Smith LM; Modi GJ; Blajchman MA
Br J Haematol; 1984 Jun; 57(2):229-38. PubMed ID: 6733045
[TBL] [Abstract][Full Text] [Related]
55. Mechanism of potentiation of antithrombin III and heparin cofactor II inhibition by sulfated xylans.
Carson L; Doctor VM
Thromb Res; 1990 May; 58(4):367-81. PubMed ID: 1972302
[TBL] [Abstract][Full Text] [Related]
56. Reaction of antithrombin with proteases. Evidence for a specific reaction with papain.
Valeri AM; Wilson SM; Feinman RD
Biochim Biophys Acta; 1980 Aug; 614(2):526-33. PubMed ID: 7407200
[TBL] [Abstract][Full Text] [Related]
57. Kinetics of the inhibition of tissue factor-factor VIIa by tissue factor pathway inhibitor.
Lindhout T; Franssen J; Willems G
Thromb Haemost; 1995 Sep; 74(3):910-5. PubMed ID: 8571320
[TBL] [Abstract][Full Text] [Related]
58. The evaluation of complex-dependent alterations in human factor VIIa.
Lawson JH; Butenas S; Mann KG
J Biol Chem; 1992 Mar; 267(7):4834-43. PubMed ID: 1537862
[TBL] [Abstract][Full Text] [Related]
59. The kinetics of hemostatic enzyme-antithrombin interactions in the presence of low molecular weight heparin.
Jordan RE; Oosta GM; Gardner WT; Rosenberg RD
J Biol Chem; 1980 Nov; 255(21):10081-90. PubMed ID: 6448846
[TBL] [Abstract][Full Text] [Related]
60. Tissue factor residues Lys165 and Lys166 are essential for rapid formation of the quaternary complex of tissue factor.VIIa with Xa.tissue factor pathway inhibitor.
Rao LV; Ruf W
Biochemistry; 1995 Aug; 34(34):10867-71. PubMed ID: 7662667
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
